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Abstract 
Adaptive immunity is based on peptide antigen recognition.  Our ability to harness the immune system for 
therapeutic gain relies on the discovery of the T cell receptor (TCR) genes that selectively target antigens 
from infections, mutated proteins, and foreign agents. Here we present a method that selectively labels 
peptide antigen-specific CD8+ T-cells in human blood using magnetic nanoparticles functionalized with 
peptide-MHC tetramers, isolates these specific cells within an integrated microfluidic device, and directly 
amplifies the TCR genes for sequencing. Critically, the identity of the peptide recognized by the TCR is 
preserved, providing the link between peptide and gene. The platform requires inputs on the order of just 
100,000 CD8+ T cells, can be multiplexed for simultaneous analysis of multiple peptides, and performs 
sorting and isolation on chip. We demonstrate 1000-fold sensitivity enhancement of antigen-specific T-
cell receptor detection and simultaneous capture of two virus antigen-specific T-cell receptors from 
samples of human blood. 
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Introduction 
A critical aspect of adaptive immunity is the engagement of T-cell receptor (TCR) proteins by 
agonist antigens presented by major histocompatibility complexes (MHCs). This interaction initiates a 
cascade of downstream signaling that promotes T cell effector functions such as cytokine secretion.1-3 To 
address the diversity of agonist antigens, the TCR relies on three variable binding domains, called 
complementarity-determining regions (CDRs). There is an outstanding need to match the TCR genes, 
especially the sequences encoding CDR3 domains, with their cognate peptide antigen-MHC (pMHC), to 
better clone therapeutic cells and model this critical interaction. This requires the isolation and TCR 
sequencing of antigen-specific T cells from a source like peripheral blood mononuclear cells (PBMCs). An 
intrinsic associated challenge is that any given antigen-specific T cell clone exists at low abundance, and 
the relatively weak binding affinity of TCRs to their cognate pMHC hampers the selective isolation of an 
antigen-specific T cell. Furthermore, TCR gene sequencing can also be confounded by the heterodimeric 
structure of the constituent α and β chains of the TCR and the highly diverse TCR repertoire.  
These challenges have prompted the development of approaches that use dye-labeled pMHC 
tetramers (for increased avidity) and fluorescence activated cell sorting (FACS)4 of single cells for TCR 
analysis. Related methods that use metal ion-labeled5, 6 or DNA-labeled7 pMHC tetramers have also been 
reported. Zhang and coworkers8 recently reported an approach in which the identity of the antigen is 
encoded using DNA tags on the pMHCs, thus permitting the linking of TCR sequences to their cognate 
antigens via single cell sequencing of FACS sorted populations. However, FACS sorting requires a large 
input of PBMCs, which can be restrictive for the analysis of non-expanded patient derived blood samples. 
Expansion to generate large enough input can alter population profiles.9-11 
We recently reported on the use of magnetic iron-oxide nanoparticles (NPs) to support the 
presentation of >104 pMHC tetramers per particle (Peng et al, under revision). These high avidity pMHC-
presenting NPs (pNPs), which can also be labeled with multi-functional DNA barcodes, permit an improved 
efficiency of antigen-specific T cell capture relative to pMHC tetramers. In particular, the pNPs enabled 
>90% recovery of antigen-specific T cells from a sample input of 105 to 106 CD8+ PBMCs, facilitating the 
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enumeration of antigen-specific T cells directly from unexpanded PBMCs.  In principle, these same pNPs 
could be used as labels for FACS sorting of single antigen-specific T cells for genetic analysis.  However, 
light scattering from the pNP barcodes renders them poor FACS labels, and so we demonstrated TCR 
sequencing by picking out individual antigen-specific T cells manually.  Here we look to develop a higher 
throughput approach that retains the avidity of pNPs for antigen-specific CD8+ T cell labeling.     
We report here on a single-stream Drop-seq derived method,12 called microfluidic antigen-TCR 
engagement sequencing (MATE-seq), for screening of barcoded pNPs against CD8+ T cells.  On-chip 
operations include purifying the pNP-labeled T cells from free pNPs, entrainment of those cells into a 
droplet-generating microfluidic circuit, and in-drop execution of RT-PCR.  The methodology required 
several advances to seamlessly integrate multiple functions onto a single microfluidic chip, as well as 
optimization of droplet chemistry for improved stability and efficiency during PCR thermal cycles.  We 
utilized the MATE-seq approach to capture and analyze rare, virus-antigen specific CD8+ T cells from 
healthy patient bloods.   
 
Experimental 
Reagents and Materials 
Unless otherwise specified, reagents were purchased from Sigma-Aldrich. Deionized water with 
resistivity of >18 megaohms∙cm was used to prepare all aqueous solutions. Roswell Park Memorial 
Institute (RPMI) 1640 Medium, phosphate buffered saline (PBS), and Calcein AM (C1430) were 
purchased from ThermoFisher Scientific (Waltham, MA). Fetal bovine serum (FBS) was purchased from 
ATCC (Mannassas, VA). Penicillin-Streptomycin mixture (17-602E) was purchased from Lonza (Basel, 
Switzerland). 3-N-Maleimido-6-hydraziniumpyridine hydrochloride (MHPH) and succinimidyl 4-
formylbenzoate (SFB) was purchased from TriLink BioTechnologies (San Diego, CA). ImmunoCult™ 
Human CD3/CD28 T Cell Activator purchased from STEMCELL Technologies Inc. (Vancouver, BC, 
Canada). Aquapel glass treatment was purchased from Pittsburgh Glass Works LLC (Pittsburgh, PA). 
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Production of SAC-DNA conjugates 
The oligonucleotide-conjugated streptavidin was produced using cysteine-modified streptavidin (SAC), 
following a previously published protocol.13 Briefly, SAC was first expressed from the pTSA-C plasmid 
containing the SAC gene (Addgene).14 SAC (1 mg/ml) was buffer exchanged to PBS containing Tris(2-
Carboxyethyl) phosphine Hydrochloride (TCEP, 5 mM) using Zeba desalting columns (Pierce).  Then 
MHPH (100 mM) in DMF was added to SAC at a molar excess of 300:1. In the meantime, SFB (100mM) 
in DMF was added to MHC-DNA (500 µM), a 5’-amine modified ssDNA (5'-NH2-AAA AAA AAA A 
TAG GCA TCC CGA GGA TTC AG), at a 40:1 molar ratio. After reacting at room temperature for 4 
hours, MHPH-labeled SAC and SFB-labeled DNA were buffer exchanged to citrate buffer (50 mM 
sodium citrate, 150 mM NaCl, pH 6.0), and then mixed at a 20:1 (DNA to SAC) molar ratio to react at 
room temperature overnight. The DNA-SAC conjugate was purified using a Superdex 200 gel filtration 
column (GE health) and concentrated with 10K MWCO ultra-centrifuge filters (Millipore). 
 
Production of DNA-labeled peptide-MHC tetramers 
We used the method of conditional antigen exchange to enable the rapid construction of HLA-A*02:01 
peptide-MHC (pMHC) by the release of a photo-labile peptide, KILGFVFJV.15-17 The photo-labile 
peptide and other peptide antigens were synthesized with standard automated Fmoc-peptide synthesis 
methodology, where J or (S)-3-(Fmoc-amino)-3-(2-nitrophenyl) propionic acid is the photo-labile amino 
acid residue. Plasmids encoding human MHC class I heavy chain and human β2m containing bacterial 
strain were kind gifts from Ton N. M. Schumacher. The MHC photo-labile protein (MHC-J) was folded 
from MHC heavy chain inclusion body, β2m inclusion body, and photo-labile peptide according to 
previously published protocol18 and then biotinylated using BirA biotin ligase. A mixture of biotinylated 
MHC-J (0.5 µM) and peptide antigen (50 µM) was exposed to 365 nm UV light for 45 minutes to 
generate the biotinylated pMHC. The peptide antigen was either CMV (NLVPMVATV), EBV 
(GLCTLVAML), MART-1 (ELAGIGILTVI) or NY-ESO (SLLMWITQV) epitope-specific. To form 
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DNA-conjugated pMHC tetramers, SAC-DNA conjugates and biotinylated pMHC were mixed at a 1:4 
(streptavidin to MHC) molar ratio, and incubated at room temperature for 30 minutes with rotation. 
 
Magnetic Nanoparticle Labeling 
NPs labeled with pMHC tetramers and DNA primers (pNPs) were formed using streptavidin coated 
magnetic NPs (500 nm radius, Dynabeads MyOne Streptavidin T1, ThermoFisher catalog #: 65601) 
according to the manufacturer’s recommended protocol for biotinylated nucleic acid attachment. The NPs 
were incubated with a mixture of biotinylated DNA (equal parts of PS1-PI-Cα, PS1-PI-Cβ and NP-DNA) 
at a 1:8 (streptavidin to biotin) molar ratio (Sup. Table 1). The DNA oligomers (synthesized by IDT) were 
biotinylated at the 5’ end. The biotins of PS1-PI-Cα and PS1-PI-Cβ were attached to the oligomer via a 
photo-cleavable group (labeled as 5PCBio in Sup. Table 1). The NP-DNA is complimentary to the SAC-
DNA. After excess DNA was washed away, the DNA-labeled pMHC tetramers and DNA-labeled NPs 
were hybridized at 37°C for 30 minutes at a molar ratio of 1.5:1 (MHC-DNA to NP-DNA), and washed 
once with 0.1% BSA and 2 mM MgCl2 in PBS. Typically, each analysis uses 2.5 µL of stock NPs (28.2 
million particles total) per antigen. 
 
Cell Culture 
Frozen leukapheresis fractions from donor NRA11 (donor 1) or NRA13 (donor 3) (UCLA IRB#03-12-
023), or commercial peripheral blood mononuclear cells from donor CMV30 (donor 2) (Cellular 
Technology Limited, Cleveland, OH) were thawed in warm cell culture media (RPMI 1640 containing 
10% FBS, 100 U/mL penicillin, and 100 µg/mL streptomycin). Thawed cells were re-suspended in cell 
culture media supplemented with IL-2 (100 IU/mL) at a density of 106 cells per mL.  The cells were first 
activated for 3 days using CD3/CD28 T Cell activator (1:40 in culture media). After 3 days, cells were re-
suspended with fresh culture media supplemented with IL-2, expanded in culture for up to 1 week, and 
frozen until use. Prior to use, the expanded specimens were thawed, and enriched for live CD8+ T cells 
using a magnetic activated cell sorting kit (Miltenyi Biotech) according to the manufacturer’s instructions. 
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 Magnetic Isolation of Antigen-specific T cells 
Live CD8+ T cells stained with calcein AM (a green-fluorescent live/dead stain, ThermoFisher) were 
incubated with pNPs for 15 min at room temperature with rotation. Free pNPs and barcoded T cells were 
enriched by magnetic isolation, and unbound cells were washed away (DynaMag™-2 Magnet, Thermo, 
12321D). The free pNPs and barcoded cells were imaged by bright field and epifluorescence microscopy 
or analyzed by MATE-seq. 
 
Device Fabrication 
The microfluidic device mold was fabricated on silicon wafers using SU-8 2025 (MicroChem). SU-8 was 
spin coated at 2000 to 4000 rpm for 60 seconds, and photolithography was performed according to the 
manufacturer’s datasheet to create feature heights ranging from 30 to 55 micrometers, as characterized by 
a profiler (Dektak). Ultraviolet (UV) light exposure was performed on a Karl Suss MA6 mask aligner, 
and the features were developed in SU-8 developer (MicroChem). To form the poly(dimethylsiloxane) 
(PDMS) device, the mold was first treated with chlorotrimethylsilane vapor for 30 minutes, and Sylgard 
184 (DOW) comprising 10:1 monomer to crosslinker mixture was poured onto the mold, degassed, and 
cured at 80°C for 2 hours. The PDMS features were cut out, and 0.7-mm or 2-mm holes were punched 
through the output or input ports, respectively. PDMS debris was removed using N2 gas, deionized water, 
and isopropanol. After the PDMS device was dried, dust was removed using tape (Scotch), and the device 
was plasma-bonded to a glass microscope slide to form the final device.  
 
Device Preparation 
The device has four inputs (I1, I2, I3, and I4) and two outputs (O1 and O2), and comprises two major 
regions: the deterministic lateral displacement (DLD) size selector and the droplet generator. The droplet 
generator was made hydrophobic by applying 1 µl of Aquapel to the device through O1. After 30 seconds 
of incubation, Aquapel was removed, and the device was dried in the oven for 30 minutes at 80°C and 
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cooled to room temperature. Each of the inputs was attached to a reagent reservoir formed from a razor-
trimmed 2-200 µL pipette tip, and the O2 output was connected to a 1-mL syringe via 50 cm Tygon 
tubing (AAD04103-CP ND-100-80, Cole-Parmer). To prime the device for use, four sets of solutions 
were sequentially infused into the device through O2 while O1 was plugged with a pin: 1) 70% ethanol 
(to remove air bubbles), 2) 3% F68 pluronic in PBS (to passivate the surface from cell and biomolecular 
fouling), 3) PBS (to wash out excess pluronic), and 4) buffer (0.73× PBS containing 100 mM NaCl, 
optimized for in-droplet RT-PCR). Around 800 µl of each solution was infused into the device through 
the 1-mL syringe at O2 using a syringe pump (New Era Pump Systems, Inc, NE-1000) set at 3 mL/hr. 
The excess solution, accumulated at the reagent reservoirs, were removed before the next solution was 
infused. 
 
Device Operation 
After the device was primed, O1 was connected to a 60 mL syringe through 2 meters of Tygon tubing 
with the syringe plunger positioned at 30 mL. To initiate the droplet generation, HFE-7500 fluorinated oil 
(3M) with 5% (w/w) PEG-PFPE amphiphilic block copolymer surfactant (008-Fluoro-surfactant, Ran 
Technologies) was loaded in I3, and a syringe vacuum pressure of around 0.75 atmosphere was applied at 
O1 by positioning the plunger at 40 mL. The plunger position was held in place by mounting the syringe 
on a syringe pump (Harvard apparatus, PHD 2000) set at a withdrawal rate of 5 mL/hr.  Once droplet 
generation was confirmed by bright field microscopy, bare pNPs, buffer, and lysis RT-PCR mix 
(described in the next section) were loaded to I1, I2, and I4, respectively. The O2 withdrawal flow rate 
(typically between 0.2 to 0.3 mL/hr) was tuned to 1) prevent the NPs from leaking into the droplet 
generator and 2) maintain a lysis RT-PCR mix to buffer ratio of about 2:1, which was determined visually 
at the flow focusing junction. Once these conditions were met, bare NPs in I1 were replaced with the 
sample (i.e. magnetically isolated antigen-specific T cells, comprising free pNPs and barcoded cells). 
Throughout the sample processing, the oil and lysis RT-PCR mix were replenished as needed, and the 
buffer level in the I2 reagent reservoir was kept higher or equal to the sample level in the I1 reagent 
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reservoir. The droplets containing lysed cells were collected inside the 2-meter Tygon tubing, which was 
placed on ice during the device operation to minimize RNA degradation. After the completion of sample 
processing, pressure was released by temporarily detaching the 60-ml syringe from the Tygon tube. 
Subsequently, the tubing was disconnected from O1 and placed into a 1.5-mL Eppendorf tube, and the 
droplets were dispensed into the tube by gently pushing the plunger of the syringe.  
 
In-Droplet RT-PCR 
The lysis RT-PCR mix described above comprises reverse transcriptase, PCR polymerase, dNTPs and 
buffer from Qiagen one step RT-PCR kit (210212), RNase inhibitor (Promega, 2U/µl), 0.25% IGEPAL 
CA 630 to lyse the cells, dithiothreitol (DTT, 5mM) to improve RT-PCR efficiency, and multiplexed 
primers α ID-Vα (Sup. Table 2) and β ID-Vβ (Sup. Table 3). In addition to the polymerase provided in 
the Qiagen kit, KOD hot DNA polymerase was added (EMD Millipore 71086, 0.02 U/µL) to increase the 
extension speed and decrease the total time necessary for the RT-PCR process. Excess oil was removed 
from the collected droplets, and the droplets were distributed in 200 µL PCR tubes. The PCR tubes were 
placed on ice and exposed to 365nm UV light (UV crosslink cat # 89131-484, VWR) for 10 minutes to 
release the ssDNA primers (PS1-PI-Cα and PS1-PI-Cβ) from the pNPs. Subsequently, RT-PCR was 
performed with the following temperature conditions: 50°C for 1 hour, 95°C for 5 min, repeat 40× of 
(94°C for 10 s, 68°C for 20 s, 70°C for 20 s), 72°C for 10 min, and hold at 12°C. Following the RT-PCR, 
the amplified DNA products were extracted from the oil droplets by adding an equal volume of 50% 
perfluorooctanol (PFO) solution in HFE-7500 to the droplets. The droplets were vortexed, centrifuged at 
1000g for 2 min, and the supernatant was recovered for subsequent gel purification and PCR.  
 
Gel Purification, PCR Enrichment, and Sequencing 
Following in-droplet RT-PCR, a series of gel purifications and PCR steps were performed to remove 
interfering oligonucleotides and non-specific amplifications, enrich for the TCR DNA, and prepare the 
products for sequencing. The amplicons from in-droplet RT-PCR were purified by agarose (1.3%) gel 
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electrophoresis, and the bands were visualized using ethidium bromide. DNA fragments between 400 and 
500 base pairs were excised and purified using a Qiagen MinElute Gel Extraction Kit, according to 
manufacturer’s instructions. The purified DNA was divided in half for enrichment PCR, amplifying TCR 
α and β gene DNA in separate reactions. The primers used are listed in Sup. Table 4, and PCR was 
performed with the following conditions: 95°C for 2 min, repeat 30× of (95°C for 20 s, 60°C for 20 s, 
70°C for 20 s), 72°C for 10 min, and hold at 12°C. Following enrichment PCR, the amplicons were 
purified by gel electrophoresis and DNA fragments between 450 and 550 base pairs were excised and 
extracted, as described above. The purified TCR α and β DNA were prepared for sequencing by adapter 
insertion PCR. This used primers listed in Sup. Table 5, and PCR was performed with the same 
conditions as described above, except the primer annealing temperature was 55°C instead of 60°C. 
Finally, the amplicons were purified by gel electrophoresis and DNA fragments between 500 to 600 base 
pairs were excised, extracted, and sent out to Laragen (Culver City, CA) for next generation sequencing. 
The sequencing was carried out on an Illumina Miseq machine using a V2 2 × 150 kit.  
 
Bulk Sequencing 
Around 1000 CD8+ cells were incubated in lysis RT-PCR buffer with RT-PCR primers PS1-PI-Cα, PS1-
PI-Cβ, and variable primers α ID-Vα and β ID-Vβ. Samples were processed in an identical fashion to in-
droplet samples in preparation for sequencing. 
 
FACS-isolated Sequencing 
Individual cells were sorted into wells of a 96-well plate containing cell lysis buffer (10mM Tris, pH=8, 
with 1 U/µl RNAse inhibitor, Promega). Following 1 hour lysis at -80 °C, the cell lysates were split in 
half to perform separate α and β gene amplification and sequenced.19 
 
Sequencing Analysis Pipeline 
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A computational sequencing analysis pipeline was developed to match reads to peptide-MHC identifiers 
(PI). The PI of each read was first isolated from the first base pair reads of the paired-end sequencing data 
(read 1). After sorting reads by PI, DNA sequences were aligned to known TCR genes and processed 
using MixCR.20 For a given antigen, the CDR3 regions of TCR genes were collected. A TCR was 
considered antigen-specific if >90% of the PIs associated with the TCR were the same. The antigen 
similarity score of a set of CDR3 sequences was defined as the average Levenshtein distance between 
each element in the set and the closest element of the entire set of CDR3 sequences that existed in the 
VDJ database21 matched to the antigen. Antigen similarity scores of sequenced CDR3s from MATE-seq 
experiments were compared to nonspecific similarity scores using 1000 random sets of 12 CDR3 
sequences sampled from bulk sequencing of T-cells and CDR3 sequences. 
 
Results & discussion 
The development of MATE-seq (Fig. 1) was motivated by the desire to understand the relationship 
between specific antigen-presenting MHC complexes and their cognate TCR genes in rare T cell 
populations. We employed the high avidity of pNPs (Fig. 1A) for antigen-specific T cell capture and TCR 
α/β gene analysis. The use of these NP reagents required that we address four challenges. First, there are 
only a handful of cells specific to a particular antigen within a given patient blood draw, and so we needed 
a microchip platform designed for efficient handling of those rare cell populations (Fig. 1B and Fig. 2).  
Second, the most efficient way to analyze a specimen is to screen the cells against a library of pNPs, where 
each library element presents a unique peptide antigen. This required further pNP engineering (primer 
design of Fig. 1A) so that the antigen identity of a pNP can be linked with the final TCR cDNA library 
sequences (Fig. 1C). Third, most pNP library elements will not bind to cells, and will need to be removed 
prior to any sequencing analysis of those cells. Thus, an on-chip purification strategy (Fig. 2A-C) is needed 
to separate the labeled cells from the unbound pNPs. Finally, labeled cells need to be analyzed individually, 
which required the incorporation of a Drop-seq type module onto the microchip (droplet generator of Fig 
1B, Fig 2D), and the development of Drop-seq chemistries (Fig 1C) to permit reverse transcription and the 
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first round of PCR to be carried out within the microdroplets used to isolate individual cells. We provide, 
below, detailed descriptions of how each of the challenges were addressed.   
 
Nanoparticle Design and Validation  
To enable TCR sequencing and antigen identification of pNP-labeled cells, we modified the 
original pNP design (Peng et al, under revision) to incorporate TCR-gene specific primers with antigen 
identifiers, as illustrated in Fig. 1A (not drawn to scale). This new pNP carries three DNA oligomers 
(Sup. Fig. 1), each performing a specific function. The first oligomer, called NP-DNA, enables the 
loading (via hybridization) of >104 pMHC tetramers onto each pNP (Peng et al, under revision). The 
second and third oligomers are photo-cleavable primers with three segments for TCR mRNA capture (Cα 
or Cβ), antigen peptide identification (PI), and RT-PCR priming (PS1). The sequences of these oligomers 
(NP-DNA, PS1-PI-Cα, and PS1-PI-Cβ) are detailed in Sup. Table 1. These oligomers are attached to the 
NP via biotin-streptavidin binding, rather than synthesized on-NP as in other bead-supported primer 
methods,12 due to the small size of the NP. The primers enable the generation of a cDNA library 
containing TCR α and β sequences, each appended with a short PI DNA barcode that identifies the 
corresponding antigen-specificity (Fig. 1C). In principle, a six-nucleotide PI can encode a library with 
4096 elements, although fewer elements are preferable to allow for error correction.22 We first validated 
that particles hybridized with NY-ESO pMHC tetramers can pull down NY-ESO-specific Jurkat cells.  As 
shown in Sup. Fig. 2, all viability stained cells were coated with pNPs, indicating that the pNPs could 
efficiently enrich the target cells by magnetic pulldown. We found that pNPs with a radius of 500 nm 
were optimal for magnetic pulldown with minimal particle sedimentation, aggregation, and non-specific 
cell collection. Most importantly, the small 500-nm radius particles establish a clear size differential from 
eukaryotic cells, enabling the use of deterministic lateral displacement (DLD)23 to separate pNPs from 
cells, as described in the next section. 
 
Sample Processing and Microfluidic Filtration 
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Fig. 1B illustrates the sample processing workflow. First, a library of pNPs (both antigen specific 
and non-specific) is mixed with CD8+ T cells, and the pNP barcoded cells and free pNPs are 
magnetically isolated from the non-labeled cells. Next, the barcoded cells and free pNPs are introduced 
onto the microfluidic platform (Fig. 2A) in parallel with buffer (Fig. 2B), permitting the cells and 
particles to interact with a DLD array.23-25 The array is a periodic arrangement of pillars designed to 
separate particles larger and smaller than a critical diameter (Dc). The key parameters and the principle of 
DLD are shown in Fig. 2C. The array is made of pillars that have a constant center-to-center distance of λ, 
which is a sum of the pillar length, Lp, and the gap size, G. Each succeeding column of pillars is vertically 
shifted down by a distance ∆λ with respect to the previous column, and the shift is reset after N columns, 
which is the period of the DLD array. The period, N, is related to λ and ∆λ, and determines the row shift 
fraction, ε, and displacement angle, θ:  
𝑁𝑁 = λ
∆λ
= 1
𝜀𝜀
= 1
𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡
     (1) 
An empirical formula has been previously derived23 for the approximation of Dc  (in µm): 
𝐷𝐷𝑐𝑐 = 1.4𝐺𝐺𝜀𝜀0.48      (2) 
 In our DLD design, we set N to 10, and therefore ε = 0.1 and θ = 5.71°. We tested a range of pillar length 
(Lp = 19 to 32.5 µm), gap size (G = 11 to 12.5 µm), center-to-center distance (λ = 30 to 45 µm), and shift 
distance (∆λ = 3 to 4.5 µm). These parameters result in a critical diameter for sorting, Dc, of around 4 to 6 
µm, meaning that any cell above this size range will be separated from free pNPs. We also tested different 
array lengths (La = 11 to 14 mm) and shapes (I-post or circles),23-28 which have been shown to affect sorting 
performance. As illustrated in Fig. 2C, the free pNPs (radius of 500 nm, <Dc) follow a “zigzag” trajectory 
toward the waste, while the barcoded cells (radius > 5 µm, >Dc) are displaced into the buffer stream toward 
the droplet generator (Fig. 2C).  
In the optimized designs (La = 14 mm, G = 12.5 µm, λ = 45 µm, and ∆λ = 4.5 µm), using either 
circular or I-shaped pillars, we achieve 100% removal of free pNPs (Fig. 2B and Sup. Movie 1) with a 
cell isolation efficiency between 60-80% (Sup. Movie 2 and 3), as represented by kymographs of flow 
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(Sup. Fig. 3) and the flow density plot of viability-stained cells at the point of separation (Fig. 2E). This is 
critical to prevent non-specific PI barcodes from being amplified during in-droplet RT-PCR, as discussed 
in the next section.  
 
In-Droplet RT-PCR Optimization 
 Droplet encapsulation of barcoded cells gives us the opportunity to link TCR genes with the specific 
peptide antigen bound to the T cell (Fig. 1B). Here, we performed RT-PCR directly in droplets, which 
maximizes capture of TCR mRNA templates and limits crosstalk of PI barcodes between cells (Fig. 1C). 
To amplify the TCR genes in droplets, we had to address several challenges. First, it was critical to 
maximize the thermal stability of the droplets so that they can withstand at least 30 cycles of PCR. We 
included up to 5% w/w PEG-PFPE amphiphilic block copolymer surfactant in the oil phase to stabilize the 
droplet interface, but still observed that larger droplets tended to burst during thermal cycling. However, if 
the droplet was too small, there were usually insufficient reagents to complete the RT-PCR reaction and 
low quality libraries were generated. The size of these droplets is determined by the nozzle height (h), flow 
focusing constriction (c), and flow rates of the droplet generator (Fig. 2D). We determined empirically that 
the maximum droplet size with the required stability was 60 µm in diameter, which was generated using a 
device that had a flow focusing nozzle height and constriction of 30 and 60 µm, respectively (Fig. 2F).  
Another challenge was tuning the protocol and reagent design of the in-droplet RT-PCR. Inside 
each droplet, a cell is lysed and its mRNA contents are released, enabling the priming of the TCR mRNA 
by PS1-PI-Cα or PS1-PI-Cβ, released from the pNPs via photocleavage (Fig 1C). RT-PCR directly on the 
pNPs without releasing the primer exhibited poor efficiency. After reverse transcription, the resulting 
cDNA is amplified using multiplexed primers α ID-Vα (Sup. Table 2) and β ID-Vβ (Sup. Table 3), which 
are included in the lysis RT-PCR reagent to prime the variable segments of the TCR. The primers bind 
close to the junction of the constant region and variable region of the TCR so that 150 base reads are 
sufficient to cover the CDR3 region. The in-droplet PCR appends the peptide identifier and flanking 
14 | P a g e  
 
.CC-BY-NC-ND 4.0 International licenseIt is made available under a 
was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint (which. http://dx.doi.org/10.1101/706606doi: bioRxiv preprint first posted online Jul. 18, 2019; 
priming sites (PS1 and α ID or β ID) to the TCR cDNA, yielding the final product in the droplet: α/β ID-
V-CDR3-C-PI-PS1 (Fig. 1C).  
 
Device Integration 
The MATE-seq device and workflow were designed to accommodate several experimental 
conditions. First, the input sample volume is low—typically <50 microliters of barcoded cell/pNP mixture 
is obtained from a pulldown, often with only a handful of barcoded cells. Such low sample volumes 
preclude syringe injection due to the high dead volume of the syringe, adapter, and tubing. Further, direct 
coupling of DLD separation to droplet generation requires a coordination of flow rates that can be 
difficult to achieve in practice. Conventional droplet generation microchips utilize syringe pumps, with 
pump flow rates precisely optimized. For example, the oil inlet is typically pumped two to three times 
faster than the aqueous inlets (e.g. cell or RT-PCR reagents).12 However, in the MATE-seq device, such a 
strategy would require coordination of 4 syringe pumps. We devised a simpler approach in which two 
syringe pumps were utilized to withdraw fluid at the outputs while, for the inputs, we used pipette tips as 
low-volume input reagent reservoirs (see Methods). 
In summary, operation of the MATE-seq device required effective separation and purification of 
free pNPs from barcoded cells, followed by cell isolation and RT-PCR within droplets. The pNPs played 
two roles.  First, they were used to selectively bind T-cells using TCR-pMHC specific interactions. 
Second, they transferred a peptide identifier (PI) barcode so that, after in-droplet RT-PCR, the TCR α and 
β genes from a specific cell carried the same PI barcode. The optimized process flow permitted efficient 
operation without additional sorting equipment. After microfluidic processing, the RT-PCR product 
undergoes two more bulk PCR and gel purification steps prior to sequencing (Fig. 3A) (see Methods). An 
optimized microfluidic design is supplied as a CAD file here (Supplementary Materials). 
 
Comparison to Bulk Analysis 
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We compared a bulk sequencing approach with MATE-seq in the analysis of PBMCs with known 
CMV-specific minorities (donor 1). Performing bulk sequencing on ~1000 of the PBMCs yielded a 
background of 144,635 unique TCR gene sequences comprising 4,129 CDR3 clones, with the most 
frequent TCR clone (α or β) consisting of 2.4 percent of the total reads (Fig. 3B, left). In the MATE-seq 
analysis, we screened the specimen against a library of pNPs, including one EBV and one CMV HLA-
A*02:01 antigen, MHC-J (as a control), and the MART-1 antigen, each with a unique PI barcode. In two 
independent analyses, 300-500 barcoded cells were processed by the microchip device, yielding 2 unique 
TCR β chains and 4 unique TCR α chains with 1 β and 3 α chains shared across both runs (Fig. 3B, right, 
Sup. Table 6). These 6 TCR genes, which were associated with the CMV barcode, represented 99.97 and 
99.56 percent of total reads detected after MATE-seq enrichment runs, respectively. In contrast, the same 
CMV-specific TCRs represented the 400th, 726th, 1387th, 1870th, 1918th, and 2869th most common clones 
from the bulk TCR analysis, occupying 0.09% of total reads. Thus, MATE-seq enriched CMV-specific 
genes by approximately 103 times, and the PI barcode provided a level of error correction against non-
specific pNP pulldowns. 
 
Comparison to Standard FACS Method 
We compared a standard FACS method with MATE-seq in the analysis of another set of PBMCs 
with known CMV specificity (donor 2). We FACS sorted and sequenced 9 single cells, yielding paired 
TCRs with 7 unique α and 5 unique β chains, as well as 4 instances of 2 α chains being isolated from the 
same single cells (Fig. 3C, left, Sup. Table 7).29, 30  Using MATE-seq, we processed ~300 cells on a 
microfluidic device and sequenced their TCR genes. This resulted in a total of 5 α and 10 β chains, 
including 2 of the 3 α chains and 1 of the 6 β chains obtained from FACS sorting (Fig. 3C, right, Sup. 
Table 8). These results demonstrate that MATE-seq was able to isolate some of the same TCR genes at 
high-throughput as the gold standard FACS method.19  
 
Multiplexed Analysis 
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Single cell encapsulation by the droplet generator allows MATE-seq to perform multiplexed TCR 
sequencing while maintaining the identity of the antigen bound in the TCR-MHC complex for each cell. 
We demonstrated this capability in the analysis of PBMCs from a mixture of donors with known CMV 
and EBV specificity (mixture of donor 1 and donor 3) (Fig. 3D). After sequencing, only 4 unique TCR 
genes were detected above the background (>99.8% of reads). Pairing the reads to the EBV or CMV 
barcodes showed that each epitope was paired with a dominant TCR pair, with good alignment with 
database predictions, as described below. We did find some evidence of cross-talk, likely due to barcode 
switching occurring after droplet breakage.  For example, the 3rd and 4th ranked EBV TCRs were the 1st 
and 2nd ranked CMV TCRs.  Thus, we only consider the top ranked TCRs for each antigen.   
 
Public Database Comparison 
The antigen specificity of a sequenced TCR gene can be supported through comparison against 
public databases.  For example, at the time of analysis, there were some 6,689 CMV (NLVPMVATV)  
antigen-specific TCR CDR3s reported21. TCRs identified against this antigen using MATE-seq should 
show similarities to this database that are not found with random TCR sequences. 
We defined the antigen similarity score of a CDR3 region as the minimum number of additions, 
deletions, or substitutions needed to convert a sequenced CDR3 to an antigen-specific CDR3 database 
element.  An exact match, for example, yields a score of 0 (Fig. 4A).21 Subsets of randomly sampled 
CDR3s from bulk sequencing (1000 subsamples of 12 CDR3s) yield an average EBV similarity score of 
~5.2 ±0.6 and an average CMV similarity score of ~4.1±0.5.  By contrast, antigens identified by MATE-
seq as CMV-specific yield an average CMV similarity score of 2 (donor 2, n=13), 3 (donor 1, n=6), and 3 
(donor 1 multiplexed analysis, n=2), and EBV-specific antigens yield an average EBV similarity score of 
0.5 (donor 3 multiplexed analysis, n=2). All combined CMV specific cells from the MATE-seq runs yield 
a CMV similarity score of 2.38 (n=21), while FACS sorted cells yield an average CMV similarity score 
of 2.17 (donor 2, n=12). 
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Exact matches between sequenced TCR genes and database TCR genes for specific antigen were 
found, but were rare. In fact, of the TCR genes reported in the database specific to CMV cells, only 8 
CDR3 genes were reported 10 times or more out of 7,186 total entries. Of these total entries 6,689 were 
unique, demonstrating the vast reported diversity of TCR genes and explaining the relative infrequency of 
exact CDR3 region matches. Yet, MATE-seq analysis uncovered exact matches for three CMV-specific 
CDR3 (CASNTGNQFYF, CAWSVSDLAKNIQYF, CASSYQTGTIYGYTF) and one EBV-specific 
CDR3 (CSARDRIGNTIYF) (Fig. 4B). These results demonstrate the capacity of MATE-seq to isolate 
likely antigen-specific T-cells for sequencing.  
 
Conclusion 
The MATE-seq method utilizes the high avidity of MHC tetramer-loaded magnetic NPs to enable 
sensitive capture of antigen specific T cell populations.  Additional engineering modifications of the NP 
scaffold, plus a custom designed microfluidic chip, enabled further genetic analysis of individual captured 
T cells, so that the TCR α and β gene sequences from a given T cell are matched with the antigen 
specificity of that cell.  The full process relied upon 3 technology innovations.  First, the NPs provided a 
modular platform to streamline multiplexing by mixing combinations of primers and binding reagents on 
the same substrate. Each pNP concentrates >104 MHC tetramers to increase the avidity of the typically 
weak TCR-pMHC interaction beyond what is achieved using pMHC tetramers.31 Second, the seamless 
integration of DLD and droplet encapsulation enabled individual purified pNP-labeled T cells to be 
captured into droplets using relatively simple and robust operating parameters.  Finally, droplet chemistry 
optimizations allowed for the first round of PCR to be carried out within the microdroplets, while 
retaining droplet integrity.  
Here we demonstrate this technology by capturing and sequencing a couple of virus antigen-
specific T cell populations from healthy patient blood, with limited multiplexing.  Future work will focus 
on increasing the library size of screened pMHCs, and on improving the chemistry associated with the in-
drop RT-PCR steps, so as to increase the information extracted from each cell.12, 32 For example, paired 
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TCR α and β chain sequences can also be generated using bridging primers, to directly link a cell’s α and 
β TCR genes physically before sequencing.33 By adding gene-specific primers for relevant T-cell genes34 
or generic polyT primers12, 32 to the pNPs, cellular phenotyping can also be carried out so that, for 
example, individual cells can be probed for signatures of antigen experience, exhaustion, or functional 
capacity.  
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 Figures 
 
Figure 1: Schematic of MATE-seq. (A) MATE-seq relies on magnetic nanoparticles, called pNPs, that 
present peptide antigens (via tetramerized MHC complexes), as well as photocleavable primers designed 
to capture TCR α or β chain mRNA for sequencing and transfer the identity of the antigen to the mRNA 
during RT-PCR. (B) A library of antigen-specific pNPs are mixed CD8+ T-cells, and pNP-bound cells 
(barcoded cells) and unbound pNPs (free pNPs) are purified by magnetic isolation. This mixture is added 
into a microfluidic device that first removes free pNPs, and then encapsulates barcoded cells in droplets. 
(C) Inside the droplets, individual cells are lysed to release their mRNA, the pNPs are exposed to UV to 
release the primers, and RT-PCR is performed. The antigen specificity of the pNPs (PI) is transferred to 
the resulting TCR cDNA library inside the droplet. After droplet breakage, the cDNA libraries are pooled 
for purification and PCR enrichment, as well as adapter insertion to prepare them for sequencing. 
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Figure 2: Microfluidic device for MATE-seq. (A) The device integrates a DLD array on the front end of 
a droplet generator, and features 4 inputs (I1 to I4) for barcoded cells-free pNPs mixture, buffer, 
encapsulation oil, and lysis/RT-PCR mix, as well as 2 outputs (O1 and O2) for the water-in-oil droplets 
created by the droplet generator and waste. (B) The barcoded cells and free pNPs are flowed in parallel 
with buffer optimized for RT-PCR with minimal mixing by diffusion. (C) After DLD processing, the 
barcoded cells are displaced into the buffer stream toward the droplet generator, with full removal of free 
pNPs into the waste. The physical dimensions of the DLD array determine a critical sorting diameter, Dc. 
(D) Barcoded cells are encapsulated in water-in-oil droplets with lysis RT-PCR mixture, and collected for 
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analysis. The size of the droplet is determined by the physical dimensions the device. The course of 
barcoded cells is shown in the micrographs of A to D, highlighted in solid red squares. (E) Fluorescent 
micrographs of viability-stained cells processed by devices with circle (top) or I-shaped (bottom) pillars. 
As the cells exit the DLD array, they tend to follow tracks defined by the pillar spacing, as seen in the 
frequency plot (inset). The intensity of the frequency plot along the y-coordinate is proportional to the 
number of cells that pass through the device at the yellow dotted line. The I-shaped pillars increased cell 
sorting efficiency into the droplet generator from ~60% to ~80%. (F) The focusing constriction (c) and 
height (h) of the droplet generator was empirically optimized to produce droplets small enough to 
withstand 30 cycles of PCR. Droplets with diameter >60 µm appear to merge into larger droplets after 
PCR, as shown in the bright field micrographs. All scale bars are 200 µm. 
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 Figure 3: MATE-seq sequencing results. (A) After microfluidic processing, the RT-PCR product was 
purified and modified with two PCR steps to generate a sequencing-ready library. Gel ladder is 100 base 
pairs. (B) The bulk analysis of cells containing CMV-specific cells (donor 1) yielded 4,129 sequenced 
TCR clones, with no single TCR contributing more than 3% of total reads. Two independent MATE-seq 
analyses of the same cells yielded 2 unique TCR β chains and 4 unique TCR α chains, all of which were 
only associated with CMV barcodes, with 1 β and 3 α chains shared across both runs. While these 6 
CDR3s contributed to >99% of total reads in MATE-seq, they only represented 0.09% of total reads from 
bulk sequencing. (C) FACS sorting and sequencing of a different set of CMV-specific T-cells (donor 2) 
yield 9 paired TCRs, with the most common α and β chains appearing in 6 and 4 cells, respectively. 
MATE-seq analysis of the same cells co-detected 3 of the same CDR3s, one of which was the most 
common α chain from FACS analysis. (D) Multiplexed MATE-seq of CMV and EBV-specific cells 
(mixture of donor 1 and 3) revealed dominant TCR α and β chains for each antigen. 
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 Figure 4: Comparison of MATE-seq with public TCR database. (A) Sequenced TCR CDR3 regions were 
compared to a public database of reported antigen-specific CDR3s. The antigen similarity score for an 
antigen-specific sequencing was defined as the average edit distance of each sequenced CDR3 to its 
nearest antigen-specific CDR3 in the database. (B) Example of CMV and EBV antigen similarity score 
matrix. Cross-antigen similarity scores showed that MATE-seq derived CDR3s for CMV and EBV were 
likely antigen-specific and far more similar to database CDR3s for the same antigen. In particular, 
MATE-seq uncovered one EBV and three CMV CDR3s with exact match to the database (i.e. score: 0) – 
one exact match from each antigen is shown. 
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